Compare Jumia Technologies AG - ADR (JMIA) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Twist Bioscience Corp — how do they compare? Jumia Technologies AG - ADR trades at $6.4 (market cap $865.90M), while Twist Bioscience Corp trades at $161.93 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 11.6× Jumia Technologies AG - ADR's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jumia Technologies AG - ADR for 28 Days and Twist Bioscience Corp for 27 Days on average.
| JMIA | TWST | |
|---|---|---|
Market Cap | $865.90M | $10.08B |
Volume | 1,695,227 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $205.00 |
52-Week Low | $5.69 | $25.45 |
Typical Hold Time | 28 Days | 27 Days |
Enterprise Value | $831.54M | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA stock trades at $6.28, down 6.82% today, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $167M in 2024 to $189M in 2025 and narrowing losses. Analyst consensus remains strong with 71% buy ratings and a $12.00 price target, supported by recent $50M capital infusion and path to EBITDA breakeven.
The outlook suggests potential upside if JMIA achieves profitability targets, but risks include persistent negative margins, high P/B ratio of 975, and competitive pressures in African e-commerce. The stock offers speculative growth potential with significant execution risk.
Twist Bioscience (TWST) trades at $159.78, up 2.65% today, showing strong momentum despite mixed technical signals. The company continues to demonstrate robust revenue growth, with 2025 revenue reaching $377 million, though profitability remains elusive with a -31.66% net income margin. Recent positive developments include a strategic partnership with Eli Lilly's TuneLab AI platform announced September 16, 2026, driving investor optimism about the company's AI-driven drug discovery capabilities.
While analyst consensus remains bullish with 73% buy ratings, the stock faces significant fundamental challenges including persistent cash burn and negative earnings. The current price exceeds the $145.20 consensus target, suggesting limited near-term upside. Key risks include execution challenges in achieving profitability and dependence on AI partnerships for growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
